Catalytically inactive anthrax toxin(s) are potential prophylactic agents
- PMID: 17980467
- DOI: 10.1016/j.vaccine.2007.09.063
Catalytically inactive anthrax toxin(s) are potential prophylactic agents
Abstract
The anthrax exotoxin, which is a key mediator of anthrax related pathogenesis, is composed of two separate toxins formed by pairwise combinations of three proteins that are encoded on the pXO1 plasmid of Bacillus anthracis. Lethal toxin is composed of protective antigen (PA) combined with lethal factor (LF) while edema toxin is composed of PA and edema factor (EF). The present study found that the catalytic mutants of LF (LFE687A) and EF (EFH351A) competitively inhibited lethal toxin and edema toxin-mediated activity in vitro and lethality in vivo and were non-toxic to sensitive cell lines when combined with PA. While PA combined with EFH351A was non-lethal in mice, PA combined with LFE687A was of reduced virulence. Full protection of mice against a lethal toxin challenge required injection of mice with PA combined with both LFE687A and EFH351A. The potential use of these full-length, biologically inactive mutant proteins combined with PA as prophylactics or therapeutics is discussed.
Similar articles
-
Protective activity and immunogenicity of two recombinant anthrax vaccines for veterinary use.Vaccine. 2008 Oct 23;26(45):5684-8. doi: 10.1016/j.vaccine.2008.08.026. Epub 2008 Sep 4. Vaccine. 2008. PMID: 18775462
-
Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein.Infect Immun. 2001 Jul;69(7):4509-15. doi: 10.1128/IAI.69.7.4509-4515.2001. Infect Immun. 2001. PMID: 11401993 Free PMC article.
-
Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens.FEMS Immunol Med Microbiol. 2008 Mar;52(2):169-79. doi: 10.1111/j.1574-695X.2007.00347.x. Epub 2008 Jan 9. FEMS Immunol Med Microbiol. 2008. PMID: 18194342
-
Molecular basis for improved anthrax vaccines.Adv Drug Deliv Rev. 2005 Jun 17;57(9):1266-92. doi: 10.1016/j.addr.2005.01.028. Epub 2005 Apr 21. Adv Drug Deliv Rev. 2005. PMID: 15935874 Review.
-
Progress and novel strategies in vaccine development and treatment of anthrax.Immunol Rev. 2011 Jan;239(1):221-36. doi: 10.1111/j.1600-065X.2010.00969.x. Immunol Rev. 2011. PMID: 21198675 Review.
Cited by
-
Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis.Open Microbiol J. 2010 Jun 3;4:34-46. doi: 10.2174/1874285801004010034. Open Microbiol J. 2010. PMID: 21127743 Free PMC article.
-
Serodiagnosis of human cutaneous anthrax in India using an indirect anti-lethal factor IgG enzyme-linked immunosorbent assay.Clin Vaccine Immunol. 2013 Feb;20(2):282-6. doi: 10.1128/CVI.00598-12. Epub 2012 Dec 26. Clin Vaccine Immunol. 2013. PMID: 23269414 Free PMC article.
-
Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.Vaccine. 2017 Jun 8;35(26):3416-3422. doi: 10.1016/j.vaccine.2017.05.006. Epub 2017 May 11. Vaccine. 2017. PMID: 28504191 Free PMC article.
-
A potent tumor-selective ERK pathway inactivator with high therapeutic index.PNAS Nexus. 2022 Jul 1;1(3):pgac104. doi: 10.1093/pnasnexus/pgac104. eCollection 2022 Jul. PNAS Nexus. 2022. PMID: 35899070 Free PMC article.
-
Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.Br J Pharmacol. 2010 Oct;161(4):721-48. doi: 10.1111/j.1476-5381.2010.00939.x. Br J Pharmacol. 2010. PMID: 20860656 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical